Business model

Macro analysis

A sector with several financing streams and, according to SiRM, long waiting lists for assessment as its biggest bottleneck. (source)

A treatment error without a budget line

Transgender care is provided by many providers and financed from several sources. The SiRM study (2023) explicitly left the financing outside its scope (source), and this site has no verified total for what the sector costs.

The four payers

Who pays?

1. Health insurers (Zvw)

Basic insurance, paid for through the premiums of all insured. Four large insurers: Zilveren Kruis, VGZ, CZ and Menzis.

2. Patients themselves

Own-risk excess and treatments that basic insurance does not cover.

3. Municipalities (Youth Act)

For minors, part of the care falls under the Youth Act, which municipalities carry out.

4. National government

Direct subsidies, among them the subsidy scheme for breast prostheses for transgender women.

Subsidy scheme not extended after 2028
In answers to parliamentary questions (Aanhangsel Handelingen 2024-2025, no. 371) the government said that the subsidy scheme for breast prostheses for transgender women will not be extended after 2028, because use is lower than expected and declining; 623 transgender women have used the scheme since 2019 (source).

Four demand scenarios — SiRM

SiRM (March 2023, for ZonMw) modelled four hypothetical scenarios for the demand for transgender care over five years (2022-2027): (a) further individualisation and tailoring, (b) greater social acceptance and awareness, (c) brief assessment and informed consent, (d) restraint with transgender care (source). SiRM stresses that scenarios are hypothetical directions, not options or expectations.

In every scenario temporary catch-up capacity is needed to shorten the waiting time. SiRM modelled catch-up capacity of 10-30% of annual new registrations: 10% is in no scenario enough to remove the waiting time before 2036, with 20% the waiting time reaches the Treeknorm between 2030 and 2040, and with 30% the waiting time disappears between 2030 and 2037, except in scenario b where it is not enough before 2031. The number of people waiting peaks between 2023 and 2028 at a little over 7,000 in scenario d to over 24,000 in scenario b (source). The financing of this capacity was outside the scope of the study.

The waiting lists

In 2022 the average wait for an intake had risen to almost two years. Of about 9,300 registered waiting, about 6,900 were unique after correcting for duplicates; SiRM called assessment the biggest bottleneck in transgender care (source).

Costs of waiting

SiRM, citing the Kwartiermaker Transgenderzorg and Transvisie (2019), writes that the long wait has a strongly negative influence on the mental wellbeing and societal position of those waiting (source). This site has no verified figure for the resulting costs elsewhere in society.

The Netherlands' position

The Netherlands sits between two poles:

UK, Sweden, Finland

UK: since March 2024 NHS England no longer routinely commissions puberty blockers for under-18s (source). Sweden (Socialstyrelsen, 2022) and Finland (2020): according to the Cass Review medical treatment is recommended only within a research framework (source).

Netherlands

Insured care; in 2022 the average wait for an intake was almost two years (source). On 30 June 2026 the Gezondheidsraad saw no reason to organise the care differently (source).

USA

In 2025 the federal health department published the review "Treatment for Pediatric Gender Dysphoria: Review of Evidence and Best Practices"; WPATH and USPATH responded jointly on 2 May 2025 (source).

Motions by Diederik van Dijk (SGP) and Hertzberger (NSC) led to the request for advice to the Gezondheidsraad (source).

Cass Review and Dutch policy

The Cass Review and Dutch policy:

  • June 2024: the minister wrote that the conclusions of the Cass Review, where relevant to the Dutch context, would be taken into the revision of the quality standard (source)
  • 2024: motions by Diederik van Dijk (SGP) and Hertzberger (NSC) led to the request for advice to the Gezondheidsraad (source)
  • Autumn 2024: the subsidy scheme for breast prostheses for transgender women will not be extended after 2028 (source)
  • 30 June 2026: the Gezondheidsraad advised that Dutch care is carefully organised and saw no reason to organise it differently, while rating the evidence for effects "low to very low" (source)

Conclusion

Transgender care in the Netherlands has several financing streams and, according to the SiRM study, long waiting lists for assessment as its biggest bottleneck (source).

Parliamentary papers and advisory reports show where policy is heading; see the Gezondheidsraad advice of 30 June 2026 (source).

Since 30 June 2026 the Netherlands has an advice of its own: the Gezondheidsraad rated the evidence for effects "low to very low" but saw no reason to organise care differently (source).

Sources

  • SiRM, Uncertainty about demand for transgender care, catch-up capacity certainly needed, March 2023
  • Radboud University / ZonMw, My gender, whose care?, February 2023
  • KPMG Health for VWS, Design body transgender care, September 2023
  • Dutch Health Care Institute, Package Agenda Appropriate Care 2023–2025
  • Evaluation Subsidy Scheme breast prostheses trans-women (open.overheid.nl)
  • Parliamentary papers 31016 nos. 346 + K; 36200-XVI no. 15; 31016 no. 365
  • Answers to parliamentary questions, Aanhangsel Handelingen 2024-2025, no. 371
  • Cass Review (NHS England, 2024); WPATH SOC 8; Amsterdam UMC response April 2024